IRVINE, Calif., Nov. 4, 2010 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company with a focus on DNA-based clinical diagnostic testing services for oncology and pre-and postnatal developmental disorders, announced today the award of $488,958 under the Internal Revenue Service's Section 48D for Qualifying Therapeutic Discovery Projects. All of this grant is available for reimbursement this month, and is for activities incurred for the following projects:
- Array Comparative Genomic Hybridization, or "aCGH"; and
- Comprehensive Cancer Array, or "CCA".
CONTACT: CombiMatrix Corporation R. Judd Jessup, President & CEO (949) 753-0624 Fax (949) 753-1504